

Radioiodine therapy for thyroid cancer doesn't up stroke risk

August 21 2017



(HealthDay)—Radioiodine (I-131) therapy for thyroid cancer is not

associated with increased risk of stroke, according to a study published online Aug. 16 in *Head & Neck*.

Chun-Yi Lin, M.D., from Show Chwan Memorial Hospital in Changhua, Taiwan, and colleagues examined the correlation between I-131 therapy for thyroid cancer and the risk of stroke among 10,104 patients aged 20 years or older newly diagnosed with thyroid cancer during 2000 to 2010. Patients were classified into two cohorts according to receipt of I-131 therapy through 1:1 propensity score matching.

The researchers found that the risk of [ischemic stroke](#) (adjusted hazard ratio, 1.05; 95 percent confidence interval, 0.82 to 1.34) or [hemorrhagic stroke](#) (adjusted hazard ratio, 1.06; 95 percent confidence interval, 0.58 to 1.93) was not significantly higher for the I-131 therapy group versus the non-I-131 therapy group, after adjustment for age, sex, and comorbidities.

"The I-131 treatment for [thyroid cancer](#) did not increase the risk of [stroke](#) during up to 10 years of follow-up," the authors write. "However, a longer follow-up period is needed to assess late adverse effects occurring after 10 years."

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Radioiodine therapy for thyroid cancer doesn't up stroke risk (2017, August 21)
retrieved 10 April 2023 from
<https://medicalxpress.com/news/2017-08-radioiodine-therapy-thyroid-cancer-doesnt.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.